Aims: The purpose of this study was to determine if a bedside test, the MMP-8 PTD Checkீ, can be of value in the antenatal identification of funisitis. This test can be performed in 15 min without any laboratory equipment.
Introduction
Funisitis is diagnosed in the presence of neutrophil infiltration of the umbilical vessels or Wharton's jelly, and the histologic hallmark of fetal systemic inflammation w13, 23, 24x. Funisitis is temporally the most advanced phase in ascending intrauterine infection w16x, and is associated with an increased risk of neonatal infection-related morbidity w13, 23x and long-term handicap such as cerebral palsy w22x.
Neutrophils in amniotic fluid (AF) are considered to be of fetal origin w17x and can release matrix metalloproteinase-8 (MMP-8), also called neutrophil collagenase, during inflammation w2, 7, 18x. Therefore, an elevated MMP-8 in AF may indicate fetal systemic inflammation.
It is well documented that an elevated concentration of AF MMP-8 is a sensitive and powerful predictor of intra-amniotic infection and/or inflammation w1, 8-10x. Moreover, recent reports have demonstrated that a rapid MMP-8 bedside test is valuable in the identification of intra-amniotic infection and/or inflammation among patients with preterm labor and intact membranes or preterm premature rupture of membranes w6, 12x. However, it has not been assessed yet that a rapid MMP-8 bedside test is valuable in the antenatal identification of funisitis. To this end, the current study was designed to determine the diagnostic performance of a rapid MMP-8 bedside test (MMP-8 PTD Checkீ; SK Parma Co, Ltd, Kyunggi-do, Korea) in the antenatal identification of funisitis in preterm gestation.
Material and methods

Study design
The relationship between the presence of funisitis and the results of an MMP-8 PTD Checkீ was examined in 139 patients who 1993 and December 1999 . At this institution, amniocentesis for retrieval of AF was offered routinely to all patients admitted with the diagnosis of preterm labor or preterm premature rupture of membranes. AF was analyzed for microbiologic status and fetal lung maturity. Amniocentesis was also performed to assess fetal lung maturity in patients with pregnancy induced hypertension. This procedure was performed after written informed consent was obtained. The Institutional Review Board approved the collection and use of these samples and information for research purposes. Many of the patients in this study were included in our previous studies.
AF and umbilical cord blood
AF was cultured for aerobic and anaerobic bacteria and for genital mycoplasmas (Ureaplasma urealyticum and Mycoplasma hominis), and analyzed for white blood cell (WBC) count. The remaining stored AF was analyzed for interleukin-6 (IL-6) and MMP-8 PTD Checkீ. IL-6 concentrations in AF were measured with a commercially available enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). The sensitivity of the test was -1.0 pg/ml. Both intra-and inter-assay coefficients of variation were -10%. Intra-amniotic inflammation (IAI) was defined as an elevated AF IL-6 concentration (G2.6 ng/mL), as previously reported w20x. Umbilical cord blood was collected in ethylene-diaminetetraacetic acid-containing blood collection tubes by venipuncture of the umbilical vein at birth. Samples were then centrifuged, and supernatants were stored in polyprophylene tubes at -708C. IL-6 concentrations in umbilical cord plasma were measured with a commercially available enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). The sensitivity of the test was 0.05 pg/mL. Both intra-and inter-assay coefficients of variation were -10%.
Rapid MMP-8 bedside test
In 2007, the MMP-8 PTD Checkீ was performed with stored AF by one of the authors (C.W.P) who was blinded to the results of the AF studies (i.e., culture results, WBC count, and IL-6 concentrations, etc.) and pregnancy outcome. In the current study, we mixed 15 mL of AF and 120 mL of buffer (1:8 mixture), which is different from the original test. The cut-off value of the modified test is 20 ng/mL of MMP-8 which is approximately similar to the cut-off value of intra-amniotic inflammation identified and used in our previous reports (23 ng/mL) w14, 19x. The results are available within 15 min without any laboratory equipment other than a pipette at the bedside. Details about the test were described in a previous report w12x.
Diagnosis of chorioamnionitis and funisitis
Histologic chorioamnionitis was defined in the presence of acute inflammatory changes on examination of a membrane roll and chorionic plate of the placenta; funisitis was diagnosed in the presence of neutrophil infiltration into the umbilical vessel walls or Wharton's jelly with the use of criteria previously published w20x. Clinical chorioamnionitis was diagnosed according to the definitions previously described in detail w22x.
Statistical analysis
The Mann-Whitney U test was used for comparison of continuous variables. Comparisons of proportions were performed with the Fisher's exact test. Logistic regression analysis was used to explore the effect of maternal age, gestational age at delivery, and presence or absence of rupture of membranes at amniocentesis on pregnancy outcome. Statistical significance was defined as a P-0.05.
Results
Funisitis and MMP-8 PTD Checkீ
Funisitis was present in 27% (38/139) of cases. The MMP-8 PTD Checkீ was positive in 97% (37/38) of cases with funisitis and in 37% (37/101) of cases without funisitis. Table 1 describes the diagnostic indices, predictive values, and likelihood ratios of an MMP-8 PTD Checkீ for the identification of funisitis and histologic chorioamnionitis. Figure 1 shows the frequency of a positive AF culture, intra-amniotic inflammation, histologic chorioamnionitis, and clinical chorioamnionitis according to the results of an MMP-8 PTD Checkீ and the presence or absence of funisitis. Patients with funisitis had significantly higher rates of a positive amniotic fluid culture, intra-amniotic inflammation, histologic chorioamnionitis, and clinical chorioamnionitis than those without funisitis but with a positive MMP-8 PTD Checkீ, and also than those without funisitis and with a negative MMP-8 PTD Checkீ (adjusted P-0.05 for each, see Figure 1 ). Among cases without funisitis, patients with a positive MMP-8 PTD Checkீ had significantly higher rates of intra-amniotic inflammation and histologic chorioamnionitis than those with a negative MMP-8 PTD Checkீ (adjusted P-0.001 for each, see Figure 1 ). Each P-value was adjusted for maternal age, gestational age at delivery, and the presence or absence of rupture of membranes at amniocentesis.
Clinical characteristics and pregnancy outcome of study population
AF inflammation and umbilical cord plasma IL-6
Figure 2 demonstrates AF IL-6 concentration, AF WBC count and umbilical cord plasma IL-6 concentration according to the results of an MMP-8 PTD Checkீ and the presence or absence of funisitis. Patients with funisitis had a significantly higher median AF IL-6 concentration, AF WBC count and umbilical cord plasma IL-6 concentration at birth than those without funisitis (P-0.05 for each, see Figure 2 ). Moreover, among cases without funisitis, patients with a positive MMP-8 PTD Checkீ had a significantly higher median AF IL-6 concentration, AF WBC count and umbilical cord plasma IL-6 concentration at birth than those with a negative MMP-8 PTD Checkீ (P-0.05 for each, see Figure 2 ).
Comment
Principal findings of the study 1) The MMP-8 PTD Checkீ was a simple and sensitive test for the antenatal identification of funisitis in preterm gestation; 2) Among patients without funisitis, patients with a positive MMP-8 PTD Checkீ had a significantly higher median AF IL-6 concentration, AF WBC count, and umbilical cord plasma IL-6 concentration at birth than those with a negative MMP-8 PTD Checkீ.
The significance of a positive MMP-8 PTD Checkீ among patients without funisitis
Patients with a positive MMP-8 PTD Checkீ had a significantly higher median AF IL-6 concentration, AF WBC count, and umbilical cord plasma IL-6 concentration at birth than those with a negative MMP-8 PTD Checkீ among patients without funisitis in the current study. This is an important observation, because it is consistent with the inference that funisitis is temporally the most advanced phase in ascending intrauterine infection and therefore an intra-amniotic inflammatory response has already occurred before the development of funisitis. Therefore, early detection of intra-amniotic and fetal inflammation by the MMP-8 PTD Checkீ in patients without funisitis may be necessary for the prediction of pregnancy outcome and management in patients at risk for preterm delivery.
The relative low positive predictive value and specificity of the MMP-8 PTD Checkீ test in the identification of funisitis, and the significance of a likelihood ratio of a negative test of MMP-8 PTD Checkீ
MMP-8 PTD Checkீ test had a low specificity (63%) and positive predictive value (50%) in the identification of funisitis, but false positive cases had a significantly higher rate of histologic chorioamnionitis and intra-amniotic inflammation than those who were true negative cases. Therefore, although the MMP-8 PTD Checkீ test had a low specificity, it was worth performing because this test could categorize patients without funisitis into two groups: those with false positive and true negative groups, which had significantly different rates of adverse pregnancy outcomes such as histologic chorioamnionitis and intra-amniotic inflammation. Moreover, as shown in Table 1 , the likelihood ratios of a positive test and a negative test of MMP-8 PTD Checkீ for the identification of funisitis were 2.66 (95% CI, 2.05-3.45) and 0.04 (95% CI, 0.01-0.29). The Evidence-Based Medicine Working Group w5x has suggested that a likelihood ratio of less than 0.1 indicates a large and often conclusive decrease in the likelihood of disease. Therefore, the results of the current study suggest that funisitis will rarely occur in patients with a negative MMP-8 PTD Checkீ result.
MMP-8 PTD Checkீ protocol
We used a cutoff of 23 ng/mL of AF MMP-8 concentration (determined by ELISA) as the definition of intra-amniotic inflammation based upon previous studies w14, 19x.
The MMP-8 PTD Checkீ, however, detects the presence of MMP-8 in human AF with a threshold of 10 ng/mL according to the original test manual, and therefore we modified the rapid test procedure to detect 20 ng/mL of MMP-8, similar to the cut off level of the definition of intra-amniotic inflammation.
A point-of-care test for the antenatal detection of funisitis As previously reported w12x, an MMP-8 rapid test has many of the optimal properties of point-of-care test which include a simple testing method, an inexpensive test to set up, and easy and rapid interpretation of the results. Therefore, in cases of preterm gestation such as preterm labor and intact membranes or preterm rupture of membranes, the antenatal detection of funisitis by means of an MMP-8 rapid test is readily feasible anywhere around the clock.
Strengths and weakness of the study
Strengths of the current study are that an MMP-8 rapid test was not used in the management of the patients and that in addition to AF MMP-8 qualitative assessment utilizing an MMP-8 rapid test, most parameters which could reflect the fetal inflammatory status in all compartments within the amniotic cavity were included, namely: (1) WBC count including neutrophils in AF, which are predominantly of fetal origin w17x; (2) umbilical cord blood IL-6, which has been originally used for the definition of the fetal inflammatory response syndrome w15x; and (3) funisitis, which is the histopathological hallmark of the fetal systemic inflammation w13, 23, 24x. It could be argued that a weakness of this study is that it was conducted with AF which was stored at -708C. However, we have previously reported that the test underwent extensive validation by the biotechnology company that produces the assay, and that there was substantial agreement between results of AF subjected to freeze-thaw cycles w12x. Although a criticism of our study could be the relatively small cohort (ns139), we demonstrated excellent diagnostic performance including a high sensitivity and low negative likelihood ratio in the antenatal identification of funisitis. Moreover, there was a significant difference in amniotic fluid and fetal inflammatory responses among patients with funisitis, those without funisitis but with a positive MMP-8 PTD Checkீ, and also those without funisitis and with a negative MMP-8 PTD Checkீ.
Clinical implication of this study
It is well known that funisitis, and an intra-amniotic and fetal inflammatory response are associated with preterm delivery and severe neonatal morbidity, including early onset neonatal sepsis or long-term handicap such as cerebral palsy w3, 4, 11, 13, 19, 21-23x. In the current study, we demonstrated that the rapid results of the MMP-8 PTD Checkீ are valuable in the antenatal identification of funisitis and the identification of patients without funisitis but with an intra-amniotic and fetal inflammatory response. Therefore, the MMP-8 PTD Checkீ could be helpful in predicting pregnancy outcome, counseling and management of patients at risk for preterm delivery due to preterm labor and intact membranes or preterm premature rupture of membranes.
Unanswered questions and proposals for future research
Further studies are needed to determine whether treatment with either antibiotics and/or tissue inhibitor of metalloproteinases (TIMP) can achieve negative conversion in cases with a positive MMP-8 rapid test, thereby improving pregnancy and neonatal outcome.
